Disease Report: Crohn's disease


Groups and Companies
Funding
Standard of Care
Unmet Medical Need
Novel Modalities and Combinations
Symptoms Evidence
Symptoms Targets
Pathogenesis Evidence
Pathogenesis Targets
Assays and Models

Certainly! Here is a comprehensive overview of patient groups, academic research groups, and companies developing drugs for Crohn's disease, based on extensive research:

1. Patient groups:

  • Crohn's & Colitis Foundation: The leading nonprofit organization focused on Crohn's disease and ulcerative colitis, providing nationwide support groups (mostly virtual), advocacy, education, and funding for research. They offer tailored support for various demographics including college students, older adults, and women.
    https://www.crohnscolitisfoundation.org
  • Crohn's and Colitis Foundation of America: Established in 1967, this foundation educates patients and the public, provides support groups, advocates for patient rights, and funds research.
    https://rarediseases.org/organizations/crohns-and-colitis-foundation-of-america/
  • Crohn's & Colitis UK: The UK’s leading charity for Crohn's and colitis, offering local networks, educational talks, social events, and support to over 40,000 members.
    https://crohnsandcolitis.org.uk
  • Project Crohns: A nonprofit focused on young adults with Crohn's disease and ulcerative colitis, providing mentorship, financial planning, and counseling.
    https://www.projectcrohns.org/
  • Inflammatory Bowel Disease Support Group (IBDsupport.org): A public education organization offering resources and support for people with IBD including Crohn's disease.
    https://www.ibdsupport.org/
  • Patient Advocate Foundation (PAF): Provides case management and financial aid to patients with chronic illnesses including Crohn's disease.
    https://www.patientadvocate.org/

2. Academic groups and institutions:


3. Companies developing a drug:

  • AbbVie Inc.: Developer of Humira (adalimumab) and Skyrizi (risankizumab), major biologics for Crohn's disease treatment. Acquired Celsius Therapeutics to expand pipeline.
    https://www.abbvie.com
  • Johnson & Johnson (Janssen Pharmaceuticals): Market leader with Remicade (infliximab) and Stelara (ustekinumab), approved for Crohn's disease. Recently submitted supplemental biologics license for Tremfya (guselkumab).
    https://www.janssen.com
  • Takeda Pharmaceutical Company Limited: Developer of Entyvio (vedolizumab), approved for Crohn's disease and ulcerative colitis.
    https://www.takeda.com
  • Hoffmann-La Roche: Active in Crohn's disease drug development pipeline.
    https://www.roche.com
  • AstraZeneca: Developing drugs targeting immune pathways for Crohn's disease.
    https://www.astrazeneca.com
  • Eli Lilly and Company: Developer of Omvoh (mirikizumab), recently FDA-approved for Crohn's disease.
    https://www.lilly.com
  • Bristol-Myers Squibb: Has Crohn's disease drug candidates in advanced clinical stages.
    https://www.bms.com
  • Gilead Sciences: Active in Crohn's disease therapeutic development.
    https://www.gilead.com
  • Biogen: Developing therapies for Crohn's disease.
    https://www.biogen.com
  • RedHill Biopharma: Developing novel therapies for Crohn's disease.
    https://www.redhillbio.com
  • Enterome: Clinical-stage biotech focused on immunomodulatory drugs targeting gut microbiome interactions in Crohn's disease.
    https://www.enterome.com
  • Evotec SE: Partnered with Crohn's & Colitis Foundation to advance drug discovery for novel IBD targets.
    https://www.evotec.com

4. Additional context:

  • There are approximately 70+ companies globally developing therapies for Crohn's disease, spanning biologics, small molecules, and novel modalities.
  • The Crohn's & Colitis Foundation plays a pivotal role in funding research, supporting patient advocacy, and investing in biotech companies to accelerate drug development.
  • Research is increasingly focused on understanding the gut microbiome, immune dysregulation, and genetic factors to develop targeted therapies.
  • Clinical trials are ongoing worldwide, with a focus on improving remission rates, reducing side effects, and addressing unmet medical needs.

5. References:

  • Crohn's & Colitis Foundation: https://www.crohnscolitisfoundation.org
  • Mass General Crohn's and Colitis Center: https://www.massgeneral.org/digestive/treatments-and-services/crohns-colitis/research
  • UCLA IBD Research Center: https://www.uclahealth.org/departments/medicine/gastro/research/themes/inflammatory-bowel-disease
  • Mayo Clinic Crohn's Disease Clinical Trials: https://www.mayo.edu/research/clinical-trials/diseases-conditions/crohns-disease
  • Mount Sinai IBD Research: https://icahn.mssm.edu/research/immunology/research/areas-of-research/ibd
  • Helmsley Charitable Trust: https://helmsleytrust.org/our-focus-areas/crohns-disease/
  • Expert Market Research, Crohn's Disease Drug Pipeline Insight Report 2025: https://www.expertmarketresearch.com/clinical-trials/crohns-disease-drug-pipeline-insight
  • GlobeNewswire, Crohn's Disease Therapeutics Pipeline Research Report 2024: https://www.globenewswire.com/news-release/2024/09/19/2949109/0/en/Crohn-s-Disease-Therapeutics-Pipeline-Research-Report-2024-Comprehensive-Insights-About-70-Companies-and-80-Drugs.html
  • Market Research Future, Crohn's Disease Market: https://www.marketresearchfuture.com/reports/crohns-disease-market/companies
  • Pharmaceutical Technology, Top Companies in IBD Space: https://www.pharmaceutical-technology.com/comment/top-companies-ibd-space/
  • Company websites as linked above.

If you need more detailed information on any specific group or company, please let me know!